by Emerson Dameron, on June 29,2017
by Emerson Dameron, on June 29,2017
In 2017, the applications and results of Volumetric Absorptive Microsampling (VAMS™) technology are gaining deeper and wider attention.
The number of publications writing about Mitra microsampling - in clinical trials, clinical research, animal testing, RNA/DNA, and beyond - has compounded over time. We've had eight new citations so far this year, and it's barely summer.
The word about Mitra microsampling has spread so rapidly that we've had to update our publications list. Have a look, and see what others have achieved.
What can 10-20 ul do for you? Contact a microsampling specialist to be part of a breakthrough in specimen collection that is changing the landscape.
The latest product releases, company news and microsampling industry updates from Neoteryx.
If you don’t find the information & assets you need via the buttons below, please contact us here: press@neoteryx.com
Contact Us
Trajan Scientific Americas Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of blood. They are CE-IVD in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada and Ukraine.
In the USA, Mitra devices are supplied as a Research-Use Only (RUO) product, to assist in method development, other research-related and non-diagnostic activities. Mitra has not been validated for use with any diagnostic testing. The suitability of Mitra for any analytical application must be evaluated and validated by the laboratory or research institute in a manner consistent with local regulatory requirements.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use.
Mitra®, VAMS® & hemaPEN® are registered trademarks owned by entities in the Trajan Group.
Copyright © 2022. All rights reserved.